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Objectives: Prostate cancer (PCA) is the most common cancer in men worldwide. 
However, there is disagreement about the benefits of existing screening programs. 
This is mainly due to low specificity of currently utilized biomarkers. This can lead 
to both inappropriate medical treatment and increasing costs of care. For the future, 
many biotechnological developments are promising, but not all will be affordable 
for routine screening. The question is how much a complementary biomarker to 
prostate-specific antigen (PSA)-test may cost which would be applied to avoid false-
positive results. MethOds: Conduct of a hybrid discrete-event and system-dynamics 
simulation by applying AnyLogic. Based on clinical guidelines and expert knowl-
edge, a hypothetical PCA screening workflow was developed and supplemented by 
a proposed innovative biomarker. Demographic and patient behavior information, 
disease related data on incidence as well as sensitivity and specificity of PSA, digital-
rectal examination and prostate biopsy were further implemented in the model. 
Economic consequences were calculated by considering costs for examinations, 
biopsy diagnosis and complications. Results: In Germany, annual screening would 
be recommended for 18.8 million men aged ≥ 45 years. Assuming a biomarker speci-
ficity of 80%, approximately 70% of prostate biopsies could be avoided. This could 
lead to a reduction of biopsy caused complications. Regarding the latter, mean costs 
of 204.17€ were calculated. Due to prevented check-ups and biopsy-complications, 
cost neutrality for the supposed biomarker will be reached when applying a price 
of 48.50€ . cOnclusiOns: A complementary biomarker could lead to more precise 
diagnosis and additional value for patients and health insurance funds. Although the 
price may not be high, an implementation may nevertheless be feasible for companies 
due to the high number of examinations. Funded by the German Federal Ministry of 
Education and Research (BMBF) as part of the National Cluster of Excellence Medical 
Technology - Medical Valley EMN (Project grant No. 01EX1013B).
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Objectives: To estimate the cost of diagnostic investigation and treatment 
for breast cancer in an Irish teaching hospital from a health payer perspec-
tive. MethOds: Retrospective population based resource utilisation data for n=611 
patients treated for primary breast cancer in a university teaching hospital in Ireland 
were available for the period 2009-2011. Health care resource use included diagnostic 
investigations and all treatments. Unit costs for diagnosis & surgical procedures, 
laboratory tests, and radiotherapy were derived from DRG costs, hospital finance 
departments, clinical opinion and literature review. Chemotherapy costs were esti-
mated from local hospital protocols, pharmacy departments and clinical opinion. 
Associated pharmaceutical cost, including oral hormonal therapy, were estimated 
from the HSE Primary Care Reimbursement Services claims database. Overall and 
mean costs by stage of breast cancer are presented with bootstrap 95% confidence 
intervals (CIs). Results: Total cost of diagnosis, treatment and follow-up was 
estimated at €15.2 million over the 3 year period, with an average cost of €24,863 
per patient (95% CI; €22,628, €27,197). Chemotherapy and other pharmaceuticals 
accounted for 47%, radiotherapy 19%, surgery 19%, diagnostics 5%, radiology 2% and 
follow-up 8% of total expenditure. The biological agent trastuzumab accounted for 
43% of total pharmaceutical expenditure. Costs varied by stage at diagnosis. The 
average cost per patient by stage at diagnosis was estimated as follows; Stage 1 (n 
= 186) €23,821 (95% CI; €20,113, €27,846); Stage 2 (n=248) €24,919 (95% CI; €21,358, 
€28,626); Stage 3 (n=121) €30,172 (95% CI; €25,434, €35,366); Stage 4 (n=56) €16,570 
(95% CI; €7,964, €25,836). cOnclusiOns: This study demonstrates the value of using 
existing data from national and local databases in estimating the cost of diagnosis 
and management of breast cancer from a health payer perspective and highlights 
the impact of trastuzumab on overall costs.
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Objectives: To estimate the frequency and costs of hospital stays for cancer 
patients receiving cytotoxic chemotherapies inducing febrile neutropenia (FN), in 
public and private hospitals in France. MethOds: The French Hospital National 
Database (PMSI) is a comprehensive claims database which includes information 
on diagnoses an procedures and allows record linkage. Hospital stays for patients 
admitted with hematologic or solid tumors in 2010/2011 were extracted and an ad 
hocalgorithm selected those for which the primary admission reason was FN, as well 
as those due to an infectious syndrome resulting from FN. Economic valuations were 
based on 2010 public national tariffs and National Scale Costs (ENCC). Results: 
A total of 14,685 hospital stays were analyzed (3,776 stays for the treatment of 
hematologic tumors and 10,909 for solid tumors) corresponding to 10,721 patients 
treated for FN (2,386 patients first treated for hematologic tumor and 8,343 first 
treated for solid tumor). The proportions of patients hospitalized for FN were 12.2% 
for hematologic tumors and 7.0% for solid tumors. The average length of stay was 
7 days for patients with hematologic tumors and 6.5 days for patients with solid 
tumors. In the sub analysis, non-Hodgkin’s lymphoma (11.7%) and lung cancer 
(11.8%) were, respectively, the most common hematologic and solid tumor types 
in patients hospitalized for FN. The mean costs of treatments associated with FN 
per patient were 7,820.67€ for hematologic tumors, 4,907.83€ for solid tumors and, 
in the sub-analysis, 6,816€ for non-Hodgkin’s lymphoma and 4,907€ for lung can-
cer. cOnclusiOns: The PMSI is a useful source to estimate the treatment costs 
associated with FN in France. In 2010/2011, febrile neutropenia induced a total of 
14,685 stays and a total cost of 59.6 million euros for the Statutory Health Insurance.
elevated liver enzymes, while dabrafenib was most often associated with CSCC 
and pyrexia. The most common AEs associated with trametinib were hyperten-
sion and rash. Common ipilimumab AEs were immune-related diarrhea/colitis, 
dyspnea, anemia, vomiting, and less frequently, hypophysitis. In the outpatient 
setting, the most costly AEs per incident included anemia (€ 1,431, € 1,309, € 1,276; 
ES, IT, FR) and CSCC (€ 1,058; NL). Other costly outpatient treatments include those 
for hypophysitis (€ 463, € 449, € 321; NL, ES, IT), febrile neutropenia (€ 593, € 430; IT, 
ES), and CSCC (€ 483, € 292; ES, IT). In the inpatient setting, the most costly AEs per 
hospitalization per country were hypophysitis (€ 10,189; ES), elevated liver enzymes 
(€ 6,868; FR), anemia (€ 2,826, € 2,628; NL, IT). Additional inpatient treatments with 
high costs were diarrhea (€ 4,083; ES), neutropenia (€ 2,322; IT) and vomiting (€ 2,036; 
NL). cOnclusiOns: Costs of managing AEs can be substantial, and effective new 
treatments with reduced AE profiles would be valuable.
PCN80
the Cost of tReatiNg squaMous Cell CaRCiNoMa of the aNus (sCCa) iN 
eNglaNd: Results fRoM aN eMPiRiCally CaliBRated Model
Keeping S.T., Carroll S.M.
Sanofi Pasteur MSD, Maidenhead, UK
Objectives: Squamous cell carcinoma of the anus (SCCA) generally requires a 
number of complex interventions as part of a multidisciplinary approach to treat-
ment. This research aimed to combine available data on disease progression 
and treatment in order to estimate the average cost of treating a case of SCCA in 
England. MethOds: Data on primary treatment, disease progression and follow-up 
were obtained from the Association of Coloproctology of Great Britain and Ireland’s 
anal cancer position statement, supplemented by expert opinion where necessary. 
First, decision trees were constructed to estimate the costs of diagnosis, staging 
and primary treatment. A Markov model was then developed to simulate disease 
progression and follow-up based on the mode of primary treatment (combined 
modality therapy versus radiotherapy alone). Values for unknown parameters were 
jointly selected from within plausible ranges and model outputs for each simula-
tion were then compared to empirical data on overall mortality and locoregional 
relapse. Goodness of fit was estimated using ordinary least squares. All costs applied 
to treatments and interventions were taken from the 2010/11 National Tariff, with 
the 2010/11 Reference Costs used for off tariff payments. A one-way sensitivity 
analysis was also performed. Results: The cost of treating a case of SCCA was 
estimated to be in the range of £16,448-£16,630 when future inflation was taken into 
account, and £16,278-£16,455 when it was not. In the one-way sensitivity analysis, 
the adjusted value ranged between £14,309-£23,264 (unadjusted £14,139-£23,077), 
with the results most sensitive to changes in the mode of admission for primary 
treatment and the costs of staging/diagnosis. cOnclusiOns: Despite limitations 
in the approach resulting from a lack of available data, these results indicate that 
the cost of treating SCCA is significant. Further observational work is required in 
order to verify these findings.
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Objectives: Information on the costs of managing adverse events (AEs) associated 
with currently-available treatment regimens in advanced melanoma is limited. This 
study identifies treatment-related AEs associated with commonly-used regimens 
recommended in US guidelines, and estimates the costs of treating these AEs in 
the US. MethOds: Grade 3 and 4 AEs were identified by a comprehensive litera-
ture search of product labels and published English-language phase II/III advanced 
melanoma studies in PubMed, conference abstracts, and NCCN guidelines. In-depth 
interviews with 5 US melanoma clinicians were performed to obtain resource uti-
lization and treatment setting information for managing each type of AE. Costs 
(2012$) were then estimated for each type of AE in outpatient and inpatient settings, 
using Medicare reimbursement rates for the outpatient setting, and Healthcare 
Utilization Project estimates for the inpatient setting. Results: The most common 
grade 3 and 4 AEs associated with chemotherapy regimens included neutropenia, 
vomiting, and anemia. Cutaneous squamous cell carcinoma (CSCC)/keratoacan-
thoma, rash, and elevated liver enzymes were most common AEs associated with 
vemurafenib, while CSCC and pyrexia were most often associated with dabrafenib. 
The most common AEs associated with trametinib were hypertension and rash. 
Common ipilimumab AEs included immune-related diarrhea/colitis, dyspnea, ane-
mia, and vomiting, and less frequent hypophysitis. The highest cost per incident 
in the outpatient setting among these AEs was neutropenia ($2,039), followed by 
CSCC ($369), vomiting ($342), and dyspnea ($222). The highest costs per hospitaliza-
tion were for CSCC ($18,906), followed by hypophysitis ($15,721) and febrile/afebrile 
neutropenia ($11,125). Other costly AEs in the inpatient setting include hypertension 
($8,113), diarrhea ($6,881), dyspnea ($6,826), vomiting ($6,046), anemia ($6,014), and 
elevated liver enzymes ($5,942). All hospitalizations due to AEs were more than 
$4,000 per incident. cOnclusiOns: The costs of managing treatment-related AEs 
in advanced melanoma are considerable, and there is need for effective treatments 
with improved toxicity profiles.
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